Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

IVIg-Primed Splenocytes Ameliorate Murine ITP in an MHC Class II-Unrestricted Manner.

Andrew R. Crow, BRT, Vinayakumar Siragam, PhD, John Freedman, MD, Alan H. Lazarus, PhD

Blood (2007) 110 (11): 102.

https://doi.org/10.1182/blood.V110.11.102.102

Published: 2007

Journal Articles

IVIg-Primed Leukocytes Offer Longer Protection in the Amelioration of ITP Than IVIg.

Andrew R. Crow, BSc, Davor Brinc, BSc, Vinayakumar Siragam, PhD, John Freedman, MD, Alan H. Lazarus, PhD

Blood (2006) 108 (11): 703.

https://doi.org/10.1182/blood.V108.11.703.703

Published: 2006

Journal Articles

Monoclonal IgG Specific for the CD44 Antigen Mimics the Action of IVIg in the Amelioration of ITP.

Seng Song, MD, Andrew R. Crow, MSc, Vinayakumar Siragam, PhD, John Freedman, MD, Alan Lazarus, PhD

Blood (2005) 106 (11): 2170.

https://doi.org/10.1182/blood.V106.11.2170.2170

Published: 2005

Journal Articles

Inhibition of Immune Thrombocytopenic Purpura (ITP) by an Orally Bioavailable Inhibitor of Syk Kinase Activity.

Andrew R. Crow, BSc, Vinayakumar Siragam, PhD, John Freedman, MD, Elliott B. Grossbard, MD, Esteban S. Masuda, PhD, Polly Pine, PhD, Alan H. Lazarus, PhD

Blood (2005) 106 (11): 2165.

https://doi.org/10.1182/blood.V106.11.2165.2165

Published: 2005

Journal Articles

Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg

Seng Song, Andrew R. Crow, Vinayakumar Siragam, John Freedman, Alan H. Lazarus

Blood (2005) 105 (4): 1546–1548.

https://doi.org/10.1182/blood-2004-05-1886

Published: 2005

Includes: Supplemental data

Journal Articles

Can IVIg Preparations with Specificity for Soluble Antigens Mimic the Therapeutic Effects of IVIg in the Treatment of Immune Thrombocytopenia?.

Vinayakumar Siragam, PhD, Davor Brinc, BSc, Andrew R. Crow, BSc, Seng Song, MD, John Freedman, MD, Alan H. Lazarus, PhD.

Blood (2004) 104 (11): 2073.

https://doi.org/10.1182/blood.V104.11.2073.2073

Published: 2004

NARROW

IVIg-Primed Splenocytes Ameliorate Murine ITP in an MHC Class II-Unrestricted Manner.

IVIg-Primed Leukocytes Offer Longer Protection in the Amelioration of ITP Than IVIg.

Monoclonal IgG Specific for the CD44 Antigen Mimics the Action of IVIg in the Amelioration of ITP.

Inhibition of Immune Thrombocytopenic Purpura (ITP) by an Orally Bioavailable Inhibitor of Syk Kinase Activity.

Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg

Can IVIg Preparations with Specificity for Soluble Antigens Mimic the Therapeutic Effects of IVIg in the Treatment of Immune Thrombocytopenia?.

Email alerts

ASH Publications

American Society of Hematology

IVIg-Primed Splenocytes Ameliorate Murine ITP in an MHC Class II-Unrestricted Manner.

IVIg-Primed Leukocytes Offer Longer Protection in the Amelioration of ITP Than IVIg.

Monoclonal IgG Specific for the CD44 Antigen Mimics the Action of IVIg in the Amelioration of ITP.

Inhibition of Immune Thrombocytopenic Purpura (ITP) by an Orally Bioavailable Inhibitor of Syk Kinase Activity.

Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg

Can IVIg Preparations with Specificity for Soluble Antigens Mimic the Therapeutic Effects of IVIg in the Treatment of Immune Thrombocytopenia?.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only